Nutropin Depot discontinued
Executive Summary
Genentech/Alkermes are discontinuing injectable human growth hormone Nutropin Depot for commercial reasons. Original form of somatropin and other delivery systems will continue to be available. Nutropin Depot represents less than 5% of Genentech's growth hormone sales, which totaled $85.5 mil. in the first quarter. Alkermes said the Nutropin Depot agreement was not profitable. Genentech is also in the midst of discontinuing the older human growth hormone brand Protropin (somatrem)...
You may also be interested in...
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.